NCT01717183Unknown不适用
Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomised, Controlled, Double-blind, European Multicentre Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 试验地点
- 1
- 主要终点
- Percentage of complete wound closure
研究概览
简要总结
The main purpose of this trial is to demonstrate that the new dressing is more effective than the current dressing in the local treatment of chronic foot ulcers in diabetic patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female over 18 years old who has provided his/her written informed consent
- •Patient covered by the French national insurance system
- •Patient with Type 1 or Type 2 diabetes mellitus with glycated hemoglobi(HbA1c) levels ≤ 10% (assayed in the previous 3 months. If not available, this assay must be performed during the run-in period)
- •Inpatient or outpatient who can be monitored by the same investigating team throughout the duration of the study
- •Patient who agrees to wear the prescribed off-loading system every day, associated with the test dressing
- •DFU with adequate arterial blood supply in the target limb DFU grade I-C or II-C as defined by the University of Texas Diabetic Wound Classification
- •Neuropathy confirmed by loss of protective sensation to monofilament test (Semmes-Weinstein 5.07 monofilament)
- •DFU located on the toe or on the lateral, dorsal or plantar side of the foot
- •Target DFU surface area between 1 cm² and 30 cm², following debridement DFU duration between 1 and 24 months
- •No local clinical infection (as defined by IDSA/IWGDF criteria) for any wound (target DFU or not) on lower limbs
- •DFU adequately debrided
排除标准
- •Pregnant or breast-feeding woman or woman of childbearing potential not using effective means of contraception
- •Patient who took part in another clinical trial in the previous month or who is to take part in another clinical trial in the 20 weeks following inclusion
- •Patient with any known intolerance or allergy or reported adverse reaction to one of the components of the trial dressings
- •Patient who has undergone surgery or surgical revascularization (vascular reconstruction or angioplasty) in the previous 2 months
- •Patient who has presented an acute ischemic event (Acute Myocardial Infarction (AMI) or stroke) in the 3 months before inclusion
- •Patient with Severe kidney failure, defined as requirement for dialysis
- •Patient with a systemic infection not controlled by suitable antibiotic treatment
- •Patient with known osteomyelitis
- •Patient with leg ulcer(s), regardless of limb
- •Patient with wounds other than the target DFU located on the heel or on the interdigital part of the foot
- •Patient with an active neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or immunosuppressant agents
- •Patient treated for a chronic disease requiring high doses of systemic corticosteroids (≥ 40 mg.d-1 of prednisolone or equivalent)
- •Patient with a severe illness that might lead to premature withdrawal from the trial
- •DFU for which surgery or surgical revascularization is planned at any time during the study
- •Deep DFU defined as stage III or IV (University of Texas Diabetic Wound Classification)
- •DFU clinically infected as defined by IDSA/IWGDF criteria
- •DFU with more than 20% of its surface area covered by black necrotic tissue following debridement
- •DFU located on an amputation stump
- •DFU with neoplastic component
结局指标
主要结局
Percentage of complete wound closure
次要结局
- Time to complete wound closure
- Change in wound surface area
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
A Clinical Study of An Antimicrobial Gauze DressingWoundsNCT00203489Tyco Healthcare Group200
Unknown
不适用
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)Venous Leg UlcerNCT04613687Laboratoires URGO52
招募中
不适用
Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional ConstipationFunctional ConstipationNCT05340712United Pharmaceuticals80
已完成
3 期
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-sensitive Prostate CancerMetastatic Prostate CancerNCT04887506Tavanta Therapeutics107
招募中
不适用
Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a european, randomised clinical trialleg ulcersDRKS00009329aboratoires URGO220